Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus

Guyton, Justinne, Jeon, Michelle, Brooks, Amie · 2019 · American Journal of Health-System Pharmacy

Abstract

Purpose: The role of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in the treatment of type 1 diabetes mellitus (T1DM), including efficacy and safety evidence, is reviewed. Summary: Currently approved treatment options for glycemic control in T1DM include insulin, which combats insulin deficiency but does not effectively target disease progression or alpha cell dysfunction; and pramlintide, whose use requires multiple daily doses and involves a high likelihood of gastrointestinal side effects. GLP-1 RAs have a unique mechanism of action in T1DM, addressing alpha cell dysfunction and thereby suppressing inappropriate glucagon secretion. GLP-1 RA dosing varies from once weekly to twice daily, and the class is well tolerated in patients with type 2 diabetes. Among the GLP-1 RAs, exenatide and liraglutide have been studied in patients with T1DM, with published evidence consistently demonstrating weight loss, decreases in total daily insulin requirements, and modest improvements in glycemic control. GLP-1 RA therapy appears to be well tolerated in patients with T1DM and is associated with nonsignificant increases in hypoglycemia risk. Conclusion: GLP-1 RA therapy represents an important add-on therapy option for achieving decreased insulin doses, weight loss, and modest improvements in HbA1c levels without significantly increasing hypoglycemia risk in patients with T1DM. Patients who have detectable C-peptide and/or are overweight or cannot achieve glycemic goals without hypoglycemia have been found to benefit the most from GLP-1 RA therapy. Further studies are warranted to evaluate these agents’ potential impact on clinical outcomes such as microvascular and macrovascular complications.

Overview

Integrity signals

Registry

Crossref · 10.1093/ajhp/zxz179

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 22 references

Research works printed but not linked: 6

  1. 2015, Symlin (pramlintide acetate) package insert
  2. 2015, Byetta (exenatide) package insert
  3. 2017, Bydureon (exenatide extended-release) package insert
  4. 2017, Victoza (liraglutide) package insert
  5. 2017, Saxenda (liraglutide) package insert
  6. Marso, 2016, Liraglutide and cardiovascular outcomes in type 2 diabetes, N Engl J Med, 375, 311, 10.1056/nejmoa1603827 · DOI · Paper page

Cited by

See all 59

Metadata

Authors
Guyton, J., Jeon, M., & Brooks, A.
Affiliations
University of Health Sciences and Pharmacy (US)
Corresponding author
Brooks, Amie
Venue
American Journal of Health-System Pharmacy
Published
2019-10-15
Volume
76
Issue
21
Pages
1739-1748
ISSN
  • 1079-2082 (ISSN-L)
  • 1535-2900
OpenAlex
W2981222478
Cited by
55
References
22
Citations by year
2026: 2 · 2025: 18 · 2024: 15 · 2023: 10 · 2022: 6 · 2021: 2 · 2020: 1 · 2019: 1
FWCI
2.04
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Health-System Pharmacy (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Keywords
GLP-1 receptor agonists, type 1 diabetes, exenatide, liraglutide, alpha-cell dysfunction, glucagon secretion, glycemic control, insulin dose reduction, weight loss, hypoglycemia risk, pramlintide, HbA1c, C-peptide
MeSH terms
Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Blood Glucose, Clinical Trials as Topic, Diabetes Mellitus, Type 1, Glucagon, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Weight Loss, Treatment Outcome, Glucagon-Secreting Cells, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus. https://app.cochat.ai/papers/10.1093/ajhp/zxz179
The paper
Guyton, J., Jeon, M., & Brooks, A. (2019). Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxz179

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.